Small study compared denosumab (20 pts) and teriparatide (21) in glucocorticoid-induced osteoporosis (GIO) Pts not responding to bisphosphonates. At 24 mos Teriparatide might have some advantages over denosumab (greater increases in LS/fem neck BMD) https://t.co/5wR9DlLfPK